Results 71 to 80 of about 16,333 (257)
Profile of alisporivir and its potential in the treatment of hepatitis C
Drug Design, Development and Therapy, 2013 Philippe A Gallay,1 Kai Lin21Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 2Permeon Biologics Inc, One Kendall Square, Cambridge, MA, USAAbstract: Two classes of hepatitis C antiviral agents currently exist,
Gallay PA, Lin K
doaj
Advanced Materials Technologies, EarlyView.Extrusion‐based bioprinting (EBB) has emerged as a versatile biofabrication platform capable of precisely depositing bioinks composed of biomaterials, cells, and bioactive agents to generate patient‐specific, biomimetic skin constructs. This paper presents a state‐of‐the‐art and forward‐looking overview of EBB for wound healing, encompassing printing ...
Hien‐Phuong Le +4 more
wiley +1 more source
Hepatitis C Treatment: A Review and Update
Southeastern European Medical Journal, 2017 Hepatitis C virus infection (HCV) infects approximately 185 million individuals worldwide. It is a leading cause of chronic liver disease and the primary reason for liver transplantation.
Jelena Jakab +4 more
doaj +1 more source
Advanced Science, EarlyView.Liu et al. define a systems‐level interactome of fibroadipogenic progenitor (FAP)‐mediated signaling in skeletal muscle by integrating single‐cell transcriptomics with FAP depletion‐based perturbation analysis. Functional interrogation using a conditioned media bioassay links predicted signaling to multicellular outcomes, establishing a framework to ...
Xingyu Liu +13 more
wiley +1 more source
Revista de Gastroenterología de México (English Edition), 2018 Aims: To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access.
S. Marciano +22 more
doaj +1 more source
Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences
Advanced Science, EarlyView.This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu +7 more
wiley +1 more source
Drug-drug interactions with direct-acting antivirals — less is more [PDF]
Clinical and Molecular Hepatology, 2021 Grace Lai-Hung Wong
doaj +1 more source
Advanced Science, EarlyView.ABSTRACT Inflammatory bowel disease (IBD) is characterized by dysregulated T cell responses. RNA helicases, including DExD‐box helicase 21 (DDX21), are pivotal in RNA metabolism, but their role in T cell‐mediated pathology during IBD remains unclear. Here, we demonstrate that DDX21 expression in CD4+ T cells correlates with cell cycle and translation ...
Yujuan Zhang +11 more
wiley +1 more source
Journal of Medical Microbiology and Infectious Diseases, 2020 Introduction: A new pathological form of HCV named as occult HCV infection (OCI) has been recently characterized by the presence of HCV RNA in liver biopsy and/or peripheral blood mononuclear cell specimens (PBMCs) and the absence of detectable ...
Elnaz Agi +7 more
doaj
UCHL3 Regulates Subgenomic Flaviviral RNA Condensates to Promote Virus Propagation
Advanced Science, EarlyView.ABSTRACT Flavivirus subgenomic RNAs (sfRNAs) antagonise antiviral defences, yet how sfRNAs are organized and maintained in cells remains poorly understood. Here we identify ubiquitin C‐terminal hydrolase L3 (UCHL3) as a post‐translational regulator of flavivirus sfRNA stability and function.
Oscar Trejo‐Cerro +7 more
wiley +1 more source